Serum fetuin A level is associated with nonalcoholic fatty liver disease in Chinese population
PDF | HTML | How to cite
Metrics: PDF 1142 views | HTML 1757 views | ?
Zhengsen Cui1,*, Rong Xuan2,* and Yunmei Yang1
1Department of Geratology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China
2Department of Endocrine, The Third Hospital of Hangzhou, Hangzhou, 310000, China
*These authors have contributed equally to the work
Yunmei Yang, email: [email protected]
Keywords: fetuin A; non-alcoholic fatty liver disease; metabolic disorder; insulin resistance; serum biomarker
Received: July 14, 2017 Accepted: September 23, 2017 Published: November 10, 2017
Objective: To investigate the association between serum fetuin A concentration and non-alcoholic fatty liver disease (NAFLD) in Chinese population.
Methods: This case-control study enrolled 79 NAFLD cases and 79 non-NAFLD controls. All subjects were selected from Chinese population who received annual health examination in the First Affiliated Hospital of Zhejiang University in 2016. NAFLD was diagnosed mainly based on abdominal ultrasonography. The severity of NAFLD was categorized by serum level of alanine aminotransferase. Serum fetuin A was measured by ELISA.
Results: Serum fetuin A level in NAFLD patients was significantly lower than that in controls (0.27±0.17 vs. 0.32±0.12g/L, P < 0.05). Compared with controls, mild NAFLD (0.24±0.16 g/L, P < 0.05) and moderate NAFLD (0.25±0.17 g/L, P < 0.05) had significantly lower concentration of fetuin A, while fetuin A level tended to slightly increase with the severity of NAFLD. The prevalence rate of NAFLD decreased (75 %, 40 %, and 36 %), as fetuin A level elevated. ROC curve of fetuin A was developed to predict the presence of NAFLD. Area under ROC was 0.656.
Conclusion: Serum level of fetuin A was lower in NAFLD patients than controls, while fetuin A level increased with the severity of NAFLD, indicating a potential predicting role of fetuin A in the development of NAFLD.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.